Acetyl-L-carnitine in hepatic encephalopathy
- 951 Downloads
Hepatic encephalopathy is a common complication of hepatic cirrhosis. The clinical diagnosis is based on two concurrent types of symptoms: impaired mental status and impaired neuromotor function. Impaired mental status is characterized by deterioration in mental status with psychomotor dysfunction, impaired memory, and increased reaction time, sensory abnormalities, poor concentration, disorientation and coma. Impaired neuromotor function include hyperreflexia, rigidity, myoclonus and asterixis. The pathogenesis of hepatic encephalopathy has not been clearly defined. The general consensus is that elevated levels of ammonia and an inflammatory response work in synergy to cause astrocyte to swell and fluid to accumulate in the brain which is thought to explain the symptoms of hepatic encephalopathy. Acetyl-L-carnitine, the short-chain ester of carnitine is endogenously produced within mitochondria and peroxisomes and is involved in the transport of acetyl-moieties across the membranes of these organelles. Acetyl-L-carnitine administration has shown the recovery of neuropsychological activities related to attention/concentration, visual scanning and tracking, psychomotor speed and mental flexibility, language short-term memory, attention, and computing ability. In fact, Acetyl-L-carnitine induces ureagenesis leading to decreased blood and brain ammonia levels. Acetyl-L-carnitine treatment decreases the severity of mental and physical fatigue, depression cognitive impairment and improves health-related quality of life. The aim of this review was to provide an explanation on the possible toxic effects of ammonia in HE and evaluate the potential clinical benefits of ALC.
KeywordsL-carnitine Acetyl-L-carnitine Ammonia Hepatic encephalopathy Cirrhosis
Michele Malaguarnera was supported by the International PhD program in Neuropharmacology of the University of Catania.
The author declares that he has no competing interests
- Di Cesare Mannelli L, Ghelardini C, Toscano A, Pacini A, Bartolini A (2010) The neuropathy-protective agent acetylL-carnitine activates protein kinase C-gamma and MAPKs in a rat model of neuropathic pain. Neuroscience 165(4):1345–1352. doi:10.1016/j.neuroscience.2009.11.021 PubMedCrossRefGoogle Scholar
- Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, Rampello L (2006) Effects of Lacetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci 51(12):2242–2247. doi:10.1007/s10620-006-9187-0 PubMedCrossRefGoogle Scholar
- Malaguarnera M, Risino C, Cammalleri L, Malaguarnera L, Astuto M, Vecchio I, Rampello L (2009) Branched chain amino acids supplemented with L-acetyl carniti ne versus BCAA treatment in hepatic coma: a randomized and controlled double blind study. Eur J Gastroenterol Hepatol 21(7):762–770. doi:10.1097/MEG.0b013e328309c791 PubMedCrossRefGoogle Scholar
- Malaguarnera M, Bella R, Vacante M, Giordano M, Malaguarnera G, Gargante MP, Motta M, Mistretta A, Rampello L, Pennisi G (2011a) Acetyl-L-carnitine reduces depression and improves quality of life in patients with minimal hepatic encephalopathy. Scand J Gastroenterol 46(6):750–759. doi:10.3109/00365521.2011.565067 PubMedCrossRefGoogle Scholar
- Malaguarnera M, Vacante M, Giordano M, Pennisi G, Bella R, Rampello L, Malaguarnera M, Li Volti G, Galvano F (2011b) Oral acetyl-L-carnitine therapy reduces fatigue in overt hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. Am J Clin Nutr 93(4):799–808. doi:10.3945/ajcn.110.007393 PubMedCrossRefGoogle Scholar
- Malaguarnera M, Vacante M, Motta M, Giordano M, Malaguarnera G, Bella R, Nunnari G, Rampello L, Pennisi G (2011c) Acetyl-L-carniti ne improves cognitive functions in severe hepatic encephal opathy: a randomized and controlled clinical trial. Metab Brain Dis 26(4):281–289. doi:10.1007/s11011-011-9260-z PubMedCrossRefGoogle Scholar
- Malaguarnera M, Vacante M, Giordano M, Motta M, Bertino G, Pennisi M, Neri S, Malaguarnera M, Li Volti G, Galvano F (2011d) L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-a 2b plus ribavirin. World J Gastroenterol 17(39):4414–4420. doi:10.3748/wjg.v17.i39.4414 PubMedCrossRefGoogle Scholar
- Rama Rao KV, Jayakumar AR, Norenberg MD (2012) Glutamine in the pathogenesis of acute hepatic encephalopathy. Neurochem Int. doi:10.1016/j.neuint.2012.01.012